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Background: Many studies have suggested different roles of Metastasis-associated protein 3 (MAT3) in
different types of human cancers. However, expression of MAT3 in primary lung cancer and its relationship
with clinicopathological factors have not been examined and the biological roles of MTA3 in lung cancer cells
are still unclear.
Methods: The expression of MAT3 mRNA and protein were detected with quantitative real-time RT-PCR and
immunohistochemical methods in 118 NSCLC samples and corresponding non-neoplastic samples. Survival
curves were made with follow-up data. The relations of the prognosis with clinical and pathological characteristics
were analyzed.
Results: The expression level of MAT3 mRNA and the positive rate of MAT3 protein were significantly higher in
NSCLC samples than that in non-neoplastic samples, and in NSCLC samples with lymph node metastasis than that
in NSCLC samples without lymph node metastasis (P < 0.01). MAT3 mRNA expression level was a risk factor of
lymph node metastasis in patients with NSCLC (P = 0.006). There were significant differences in survival curves
between lymph node metastatic group and non-metastatic group (P = 0.000), among groups of MAT3 positive and
negative (P = 0.000), among groups of TNM stage I, II and III (P = 0.000) and among groups of tumor status T1, T2
and T3T4 (P = 0.000); but no statistical significance between male patients and female patients (P = 0.516), between
≥60 years old patients and <60 years old patients (P = 0.133), between histology types adenocarcinoma and
squamous cell carcinoma (P = 0.865) and between well differentiation and moderate-poor differentiation (P = 0.134).
The level of MAT3 mRNA (P = 0.000) and protein (P = 0.000) were risk factors of survival.
Conclusion: Our study showed that MAT3 over-expression in NSCLC tissue, and MAT3 mRNA level is a risk factor
of lymph node metastasis. The level of MAT3 mRNA and protein were risk factors of survival in patients with NSCLC.
It suggested that this antigen could be used as a simple and efficient parameter with which to identify high-risk
patients.
Virtual slides: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
5585901065503943.
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Metastasis-associated protein 3 (MTA3) was originally
found as a member of a small protein family (including
MTA1, MTA2 and MTA3), which is a constituent of the
Mi-2/nucleosome remodeling and deacetylase (NuRD)
protein complex that regulates gene expression by altering* Correspondence: gjzhangzzu@126.com; zhaogq@zzu.edu.cn
3Department of Respiratory Medicine, the First Affiliated Hospital of
Zhengzhou University, Zhengzhou 450052, China
2College of Basic Medical Sciences, Zhengzhou University, No.100 Kexue
Road, Zhengzhou 450001, China
Full list of author information is available at the end of the article
© 2013 Zheng et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orchromatin structure and can facilitate cohesin loading
onto DNA [1-8].
MTA3 was reported to participate in B lymphocyte
development, in plasmacytoma cell lines, the overex-
pression of BCL6 (B-cell CLL/lymphoma 6) and MTA3
downregulated plasma cell differentiation genes [9].
Since then, however, the expression of MTA3 has been
found reduced in breast cancer, endometrial cancer and
ovarian cancer [10-12]. MTA3 upregulation prevents
epithelial-mesenchymal transition (EMT) by directly
repressing Snail expression, thereby upregulating E-Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.











Tumor stage T1 39
T2 55
T3–4 24
TNM stage I 52
II 42
III 24
Node status Positive 49
Negative 69
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MTA3 was reported as an independent and unfavorable
prognostic marker in uterine non-endometriod car-
cinoma [14]. These findings suggest that the expression
of MTA3 is closely related to invasiveness, metastasis
and prognosis of tumour.
Lung cancer is one of the leading causes of all cancer-
related deaths worldwide and its incidence is increasing
[15,16]. The majority of diagnosed lung cancer cases are
non-small-cell lung cancers (NSCLCs). Many previous
studies showed the expression and functions of proteins,
genes and enzymes in lung cancer [8,17,18]. However,
expression of MTA3 mRNA and protein in primary lung
cancer and its relationship with clinicopathological fac-
tors has not been examined and the biological roles of
MTA3 in lung cancer cells are still unclear.
To explore the role of MTA3 in NSCLC, we analysed
118 cases of NSCLC patients retrospectively between
2001 and 2005, detected the expression of MTA3 mRNA
and protein with real time RT-PCR and immunohisto-
chemical methods, and explore the relationship between




Between 1.1.2001 and 31.7.2005, 118 patients with
NSCLC were enrolled in this study from Wuhan General
Hospital of Guangzhou Military and the First Affiliated
Hospital of Zhengzhou University. Patients who had
recurrent NSCLC or primary NSCLC but received che-
moradiotherapy before surgical operation were excluded.
Of the 118 patients, 59 were female and 59 were male.
And there were 49 cases with lymph node metastasis, 69
cases without lymph node metastasis. We obtained paired
NSCLC and adjacent non-tumor lung tissues (located
more than 5 cm away from the tumors) from 118 patients
who underwent primary surgical resection of NSCLC with
informed consent. Both tumor and non-tumor samples
were confirmed as such by pathological examinations.
These samples were snap-frozen in liquid nitrogen after
resection. This study was approved by the ethics commit-
tee of Zhengzhou University and informed consent was
obtained from each patient (Table 1).
Immunohistochemistry
The MTA3 protein was detected by a rabbit polyclonal
antibody (Santa Cruz USA). The sections were stained
with streptavidin peroxidase (SP) kit (Maixin Biotechno-
logy Company, China), visualized with DAB coloration
kit (Boaosen Company, China), followed by counter-
staining of campeachy, dehydration, transparency and
mounting [17]. All slides were evaluated by two different
pathologists and then in conference in a blinded mannerwithout any prior knowledge of the clinicopathological
parameters. Negative controls of immunohistochemical
reactions were performed by omitting the primary anti-
body. Replacement of primary antibody by PBS was used
as blank control. Staining intensity was modified. Briefly,
gray-scale digitized images were imported into the Op-
timas software (Optimas 6.0, Optimus Corp., Bothell,
WA, USA). Control staining (without primary antibody)
was used for the extraction of the background staining.
In every case, control reactions were included, in which
specific antibody was substituted by the Primary Mouse
Negative Control.
Real-time fluorescent quantitative RT-PCR
MTA3 and GAPDH primers were designed according
to MTA3 mRNA (NM_020744) and GAPDH mRNA
(NM_002046) with Oligo 6.0 software. The sequences
were as follows: MTA3 sense 5′ TATCAGGGGAAAG
TGCAGTGTTG 3′, MTA3 antisense 5′-AACAGCAT
TTCTGGAATGTCTGC-3′, GAPDH sense 5′-GCAAA
TT CCATGGCACCGTCAAG-3′, GAPDH antisense 5′-
GTGGTGAAGACGCCAG TGGACTC-3′. The length
of fragments amplified by PCR with MTA3 primers and
GAPDH primers were 183 bp and 151 bp, respectively.
All the primers were synthesized by Sangon Biotech
(Shanghai) Co., Ltd. RNAs were extracted from 118
NSCLC samples with RNA extraction kit (Qiagen) and
then cDNAs were synthetized by AMV (Promega). Ali-
quots of the reaction mixture were used for the qPCR
amplification with the IQ5 system (Bio-Rad) using IQ
SYBR Green Supermix (Bio-Rad). The PCR was run for
Figure 1 Immunohistochemical staining of MTA3 in lung cancer tissue sections. a and b: Positive MTA3 staining in a case of lung
adenocarcinoma. c and d: Positive MTA3 staining in a case of squamous cell carcinoma.
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55°C for 15 sec and elongation at 72°C for 15 sec. Gene
expression was quantified by the comparative CT
method, by normalizing CT values to the housekeeping
gene GAPDH. After amplification, melting curve ana-
lysis was performed to ensure the specificity of the
products.Table 2 Expression of MTA3 mRNA and protein in the 118 NS
Parameter MTA3 mRNA
Expression level P value
Gender
Male 0.2547 ± 0.10485 0.581
Female 0.2442 ± 0.10298
Age (years)
≥60 0.2646 ± 0.09439 0.073
<60 0.2302 ± 0.11224
Histology
Adeno 0.2444 ± 0.10711 0.534
SCC 0.2565 ± 0.09913
Differentiation
Well 0.2234 ± 0.11671 0.038*
Moderate-poor 0.2661 ± 0.09131
Tumor stage
T1 0.2233 ± 0.10521
T2 0.2485 ± 0.10680 0.030*
T3–4 0.2942 ± 0.07934
TNM stage
I 0.2350 ± 0.10463 0.079
II 0.2435 ± 0.10970
III 0.2913 ± 0.08077
Nodal status
Positive 0.2810 ± 0.08593 0.003*
Negative 0.2270 ± 0.10969
*Indicated statistical significance (P < 0.05).Statistical analysis
Statistical analysis was performed using SPSS17.0 soft-
ware. Data were expressed as means ± standard devia-
tion (SD). Student’s t test was used in the comparison of
mean between two samples. Fourfold table Chi square
test was used in the comparison of ratios between two




















Figure 2 (See legend on next page.)
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Figure 2 Kaplan–Meier curves of the clinical outcome for MTA3 regarding MTA3 immunolabelling. a: Schematic representation shows
survival curves of lymph node metastatic group and non-metastatic group in patients with NSCLC (P = 0.000). b: Schematic representation shows
survival curves of different MTA3 protein level groups in patients with NSCLC (P = 0.000). c: Schematic representation shows survival curves of
different TNM stages in patients with NSCLC (P = 0.000). d: Schematic representation shows survival curves of different tumor stages in patients
with NSCLC (P = 0.000). e: Schematic representation shows survival curves of different genders in patients with NSCLC (P = 0.516). f: Schematic
representation shows survival curves of different ages in patients with NSCLC (P = 0.133). g: Schematic representation shows survival curves of
different histology types in patients with NSCLC (P = 0.865). h: Schematic representation shows survival curves of differentiations in patients with
NSCLC (P = 0.134).
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The follow-up data was analyzed by the Kaplan-Meier
method and log-rank test. Cox proportional hazards
model were used in multivariate prognostic analysis. P
values less than 0.05 were considered statistically
significant.
Results
MTA3 mRNA is over-expressed in NSCLC samples and is a
risk factor of lymph node metastasis
MTA3 mRNA is over-expressed in NSCLC samples and is
a risk factor of lymph node metastasis. The relative
expression level of MTA3 mRNA was significantly higher
in NSCLC samples (118 samples, 0.2494 ±0.10361) than
that in non-neoplastic samples(118 corresponding sam-
ples, 0.1578 ± 0.07694) (P = 0.002), and in NSCLC samples
with lymph node metastasis(49 samples, 0.2810 ± 0.08593)
than that in NSCLC samples without lymph node metas-
tasis (69 samples, 0.2270 ± 0.10969) (P = 0.003) (Table 1).
Logistic regression analysis indicated that the relative
expression level of MTA3 mRNA was a risk factor of
lymph node metastasis in the patients with NSCLC (Wald
χ2 = 7.493, P = 0.006).
Positive rate of MTA3 protein is high in NSCLC samples
and associated with lymph node metastasis
MTA3 showed positive immuno-reactivity mainly in nu-
cleus and cytoplasms of the cells (Figure 1). The positive
rate of MTA3 protein expression was significantly higher
in NSCLC samples (59.32%, 70/118) than that in non-
neoplastic samples (0.00%, 0/118), and in NSCLC
samples with lymph node metastasis (79.59%, 39/49)
was higher than that in NSCLC samples without lymph
node metastasis (44.93%, 31/69) (P =0.000). Statistical
differences were found between different ages (P =
0.038), differentiation (P = 0.001), tumor stage (P =
0.018) and TNM stage (P = 0.018) (Table 2). There were
no statistical differences between different genders (P =
1.000) and histology (P = 0.849) (Table 2).
Expression level of MTA3 mRNA and protein are risk
factors of survival in patients with NSCLC
Survival curves were drawn using SPSS17.0 software with
Kaplan-Meier method. Log-rank test indicated that therewere significant differences in survival curves between
lymph node metastatic group and non-metastatic group
(χ2 =22.810, P = 0.000, Figure 2a), among groups of MTA3
protein expression positive and negative (χ2 = 52.161,
P = 0.000, Figure 2b), among groups of TNM stage I,
II and III (χ2 = 27.037, P = 0.000, Figure 2c) and among
groups of tumor status T1, T2 and T3T4 (χ2 = 37.585,
P = 0.000, Figure 2d); but no significant differences
between male patients and female patients (χ2 = 0.423,
P = 0.516, Figure 2e), between ≥60 years old patients
and <60 years old patients (χ2 = 2.261, P = 0.133, Figure 2f),
between histology types (adeno and SCC) (χ2 = 0.029,
P = 0.865, Figure 2g) and between well differentiation
and moderate-poor differentiation (χ2 = 2.249, P = 0.134,
Figure 2h).
Discussion
MTA3 is the latest addition to the MTA family. It was
identified as an estrogen-dependent component of the
Mi-2/NuRD transcriptional corepressor in breast epithe-
lial cells [8]. Through a MTA3-NuRD complex, MTA3
represses Wnt4 transcription and Wnt4 secretion,
inhibiting Wnt-target genes in mammary epithelial cells
[18,19]. The absence of MTA3 as well as the absence of
estrogen receptor (ER) results in an aberrantly increased
expression of the transcriptional repressor Snail, a mas-
ter regulator of EMT [20-22]. It has also been reported
that expression of MTA3 inhibits ductal branching in
virgin and pregnant mammary glands in MTA3-
transgenic mice [23], where the inappropriate develop-
ment of mammary glands results in the development of
hyperplastic nodules and mammary tumors, including
adenocarcinomas and lymphomas [24-26]. Considering
the many reports showing the clinical relevance of the
expression of MTA3, it is likely that MTA3 represents
master co-regulatory molecules involved in the carcino-
genesis and progression of various malignant tumors.
This study confirmed the presence of MAT3 over-
expression in NSCLC samples for the first time. The
expression level of MAT3 mRNA and the positive rate
of MAT3 protein expression were significantly higher in
NSCLC samples (0.2494 ±0.10361 and 59.32%) than that
in non-neoplastic samples (0.1578 ± 0.07694 and 0.00%),
and in NSCLC samples with lymph node metastasis
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samples without lymph node metastasis (69 samples,
0.2270 ± 0.10969) (all P < 0.01). The expression level
of MAT3 mRNA was positively correlated with lymph
node metastasis, and was a risk factor of lymph node
metastasis in the patients with NSCLC (Wald χ2 = 7.493,
P = 0.006). There were significant differences in survival
curves between lymph node metastatic group and non-
metastatic group (χ2 =22.810, P = 0.000), among groups of
MAT3 protein expression positive and negative (χ2 =
52.161, P = 0.000), among groups of TNM stage I, II and
III (χ2 = 27.037, P = 0.000) and among groups of tumor
status T1, T2 and T3T4 (χ2 = 37.585, P = 0.000); but no
significant differences between male patients and female
patients (χ2 = 0.423, P = 0.516), between ≥60 years old pa-
tients and <60 years old patients (χ2 = 2.261, P = 0.133),
between histology types (adeno and SCC) (χ2 = 0.029,
P = 0.865) and between well differentiation and moderate-
poor differentiation (χ2 = 2.249, P = 0.134). The level of
MAT3 mRNA and protein were risk factors of survival,
but lymph node metastasis was not a risk factor of survival
in the patients with NSCLC. These results suggest that
there is MAT3 over-expression in NSCLC samples and
the level of MAT3 mRNA is a risk factor of lymph node
metastasis and survival in the patients with NSCLC. The
results may provide a basis for exploring the role of
MAT3 in NSCLC. The expression level of MAT3 is
expected to become an important index to assess NSCLC
invasion and metastasis, and MTA3 may be a useful
marker to assess and identify high-risk patients with
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